There have been some anecdotal reports of patients who were prescribed a 5-day course of paxlovid initially recovering and testing negative, only to test positive again a few days later. Some of these patients experienced symptoms, but so far the FDA says there has not been an increased risk of hospitalization or death. The frequency with which the rebounds occur is unknown. About 1-2% of people in Pfizer’s clinical trial saw a rebound, but the rate was similar between those who were given paxlovid and those who received a placebo. If you experience a rebound of COVID shortly after completing a course of paxlovid, report it here.